BR112018013979A2 - composições em gel para liberação transdérmica para maximizar as concentrações de fármacos no estrato córneo e no soro e métodos de uso dos mesmos - Google Patents
composições em gel para liberação transdérmica para maximizar as concentrações de fármacos no estrato córneo e no soro e métodos de uso dos mesmosInfo
- Publication number
- BR112018013979A2 BR112018013979A2 BR112018013979A BR112018013979A BR112018013979A2 BR 112018013979 A2 BR112018013979 A2 BR 112018013979A2 BR 112018013979 A BR112018013979 A BR 112018013979A BR 112018013979 A BR112018013979 A BR 112018013979A BR 112018013979 A2 BR112018013979 A2 BR 112018013979A2
- Authority
- BR
- Brazil
- Prior art keywords
- serum
- methods
- stratum corneum
- transdermal delivery
- gel compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 210000002966 serum Anatomy 0.000 title abstract 2
- 210000000434 stratum corneum Anatomy 0.000 title abstract 2
- 230000037317 transdermal delivery Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Abstract
são divulgadas aqui composições em gel para liberação transdérmica melhorada de um ingrediente ativo em um soro de um sujeito por meio da produção de um reservatório do ingrediente ativo no estrato córneo do sujeito. são ainda divulgados métodos de uso da composição em gel para pelo menos parcialmente melhorar uma condição e kits compreendendo a composição em gel.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR122023025444-9A BR122023025444A2 (pt) | 2016-01-07 | 2017-01-06 | Composição de gel estável, e, método de preparação de uma composição em gel estável |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662275955P | 2016-01-07 | 2016-01-07 | |
US201662371670P | 2016-08-05 | 2016-08-05 | |
PCT/US2017/012564 WO2017120492A1 (en) | 2016-01-07 | 2017-01-06 | Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018013979A2 true BR112018013979A2 (pt) | 2018-12-11 |
Family
ID=58463817
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018013979A BR112018013979A2 (pt) | 2016-01-07 | 2017-01-06 | composições em gel para liberação transdérmica para maximizar as concentrações de fármacos no estrato córneo e no soro e métodos de uso dos mesmos |
BR122023025444-9A BR122023025444A2 (pt) | 2016-01-07 | 2017-01-06 | Composição de gel estável, e, método de preparação de uma composição em gel estável |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122023025444-9A BR122023025444A2 (pt) | 2016-01-07 | 2017-01-06 | Composição de gel estável, e, método de preparação de uma composição em gel estável |
Country Status (13)
Country | Link |
---|---|
US (2) | US20170196896A1 (pt) |
EP (2) | EP4091601A1 (pt) |
JP (2) | JP7055754B2 (pt) |
KR (1) | KR20180117103A (pt) |
CN (1) | CN108712901A (pt) |
AU (2) | AU2017206048B2 (pt) |
BR (2) | BR112018013979A2 (pt) |
CA (1) | CA3010829A1 (pt) |
ES (1) | ES2949053T3 (pt) |
GB (1) | GB2551598B (pt) |
IL (2) | IL300437A (pt) |
MX (2) | MX2018008467A (pt) |
WO (1) | WO2017120492A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
GB2581876B (en) * | 2017-06-22 | 2023-05-31 | Viramal Ltd | Compositions for use in the treatment of endometrial disorder |
WO2019093780A1 (ko) * | 2017-11-10 | 2019-05-16 | (주)아모레퍼시픽 | 바이겔 타입의 화장료 조성물 |
CN108635330B (zh) * | 2018-04-17 | 2021-11-30 | 上海普特生物科技有限公司 | 一种长效缓释黄体酮凝胶剂组合物 |
CN112739334A (zh) * | 2018-07-30 | 2021-04-30 | 拜欧西亚制药公司 | 结晶丙二酸肾上腺素盐 |
WO2020084548A1 (en) * | 2018-10-26 | 2020-04-30 | Viramal Limited | Mucoadhesive gel composition |
EP3659583B1 (en) * | 2018-11-30 | 2023-06-07 | Viramal Limited | A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent |
EP3922235A1 (en) * | 2020-06-11 | 2021-12-15 | Viramal Limited | A hydroalcoholic gel and a method of manufacturing said gel |
WO2022167359A1 (en) * | 2021-02-02 | 2022-08-11 | DuPont Nutrition USA, Inc. | An aqueous gel composition comprising an ethylcellulose |
CN112970804A (zh) * | 2021-03-29 | 2021-06-18 | 陕西农产品加工技术研究院 | 一种基于甘油二酯油凝胶的枸杞面包及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US618323A (en) | 1899-01-24 | Berndt e | ||
FR2739559B1 (fr) * | 1995-10-05 | 1997-11-28 | Innothera Lab Sa | Gel pour hormonotherapie locale de la secheresse vaginale |
ES2228044T3 (es) * | 1998-06-03 | 2005-04-01 | Jean-Marc Aiache | Mezcla de gel estable en forma de una mezcla de oleogel y gel acuoso. |
FR2779438B1 (fr) * | 1998-06-03 | 2004-12-24 | Jean Marc Aiache | Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant |
ES2237298B1 (es) * | 2003-07-16 | 2006-11-01 | Italfarmaco, S.A. | Formulaciones mucoadhesivas semisolidas. |
RU2007133503A (ru) * | 2005-02-10 | 2009-03-20 | Орексо Аб (Se) | Новые фармацевтические композиции, пригодные для трансмукозального введения лекарств |
DE102005037844A1 (de) * | 2005-08-04 | 2007-04-05 | Intendis Gmbh | Wasserfreies Mehr-Phasen-Gel-System |
GB2445539A (en) * | 2006-12-29 | 2008-07-16 | Ardana Bioscience Ltd | Bigel composition |
US8475774B2 (en) * | 2010-02-08 | 2013-07-02 | Johnson & Johnson Consumer Companies, Inc. | Sunscreen compositions comprising an ultraviolet radiation-absorbing polymer |
EP2603587B1 (en) * | 2010-08-09 | 2015-10-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for the treatment and prevention of hiv-1 infections |
CN109481394B (zh) * | 2011-05-15 | 2023-05-05 | 埃瑟尔斯生物医药有限公司 | 鼻内睾酮生物粘合性凝胶制剂及其治疗男性性腺功能减退症的用途 |
US11154535B2 (en) * | 2012-07-31 | 2021-10-26 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
WO2014026707A1 (en) * | 2012-08-13 | 2014-02-20 | Edko Pazarlama Tanitim Ticaret Limited Sirketi | Anti-vaginitis compositions with improved release and adherence |
-
2017
- 2017-01-06 EP EP22179555.2A patent/EP4091601A1/en active Pending
- 2017-01-06 JP JP2018554642A patent/JP7055754B2/ja active Active
- 2017-01-06 BR BR112018013979A patent/BR112018013979A2/pt active Search and Examination
- 2017-01-06 US US15/400,517 patent/US20170196896A1/en not_active Abandoned
- 2017-01-06 AU AU2017206048A patent/AU2017206048B2/en active Active
- 2017-01-06 BR BR122023025444-9A patent/BR122023025444A2/pt unknown
- 2017-01-06 GB GB1700220.5A patent/GB2551598B/en active Active
- 2017-01-06 ES ES17736445T patent/ES2949053T3/es active Active
- 2017-01-06 EP EP17736445.2A patent/EP3399963B1/en active Active
- 2017-01-06 MX MX2018008467A patent/MX2018008467A/es unknown
- 2017-01-06 KR KR1020187022738A patent/KR20180117103A/ko unknown
- 2017-01-06 IL IL300437A patent/IL300437A/en unknown
- 2017-01-06 CN CN201780015750.8A patent/CN108712901A/zh active Pending
- 2017-01-06 CA CA3010829A patent/CA3010829A1/en active Pending
- 2017-01-06 WO PCT/US2017/012564 patent/WO2017120492A1/en active Application Filing
-
2018
- 2018-07-06 MX MX2022008277A patent/MX2022008277A/es unknown
- 2018-07-08 IL IL260462A patent/IL260462B2/en unknown
-
2021
- 2021-05-18 US US17/323,496 patent/US20210338693A1/en active Pending
-
2022
- 2022-04-06 JP JP2022063361A patent/JP2022088646A/ja active Pending
-
2023
- 2023-03-20 AU AU2023201712A patent/AU2023201712A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
GB2551598B (en) | 2022-03-09 |
EP3399963B1 (en) | 2023-06-07 |
KR20180117103A (ko) | 2018-10-26 |
BR122023025444A2 (pt) | 2024-02-20 |
IL260462B2 (en) | 2023-07-01 |
EP4091601A1 (en) | 2022-11-23 |
US20210338693A1 (en) | 2021-11-04 |
IL260462B1 (en) | 2023-03-01 |
GB2551598A (en) | 2017-12-27 |
JP2022088646A (ja) | 2022-06-14 |
AU2017206048B2 (en) | 2023-04-13 |
JP2019505583A (ja) | 2019-02-28 |
CA3010829A1 (en) | 2017-07-13 |
EP3399963C0 (en) | 2023-06-07 |
AU2017206048A1 (en) | 2018-08-16 |
MX2022008277A (es) | 2022-08-04 |
AU2023201712A1 (en) | 2023-04-20 |
IL260462A (pt) | 2018-08-30 |
WO2017120492A1 (en) | 2017-07-13 |
ES2949053T3 (es) | 2023-09-25 |
EP3399963A4 (en) | 2019-09-04 |
CN108712901A (zh) | 2018-10-26 |
JP7055754B2 (ja) | 2022-04-18 |
US20170196896A1 (en) | 2017-07-13 |
IL300437A (en) | 2023-04-01 |
GB201700220D0 (en) | 2017-02-22 |
EP3399963A1 (en) | 2018-11-14 |
MX2018008467A (es) | 2019-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018013979A2 (pt) | composições em gel para liberação transdérmica para maximizar as concentrações de fármacos no estrato córneo e no soro e métodos de uso dos mesmos | |
BR112015019657A2 (pt) | composições tópicas e métodos de uso das mesmas | |
BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
BR112019009529A2 (pt) | novos derivados de quinolina | |
BRPI0615292A8 (pt) | composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada | |
BR112014011841A2 (pt) | material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos | |
CO2019009221A2 (es) | Composición farmacéutica que comprende selexipag | |
CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
AR047928A1 (es) | Derivados de tetrahidropiridoindol | |
BR112013010853A2 (pt) | "agentes citotóxicos compreendendo derivados de ansamitocina, composição farmacêutica e uso destes" | |
CR20190433A (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
PH12017500136A1 (en) | Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof | |
ES2543957T3 (es) | Nueva composición farmacéutica para el tratamiento de infecciones fúngicas | |
BR112015017246A2 (pt) | formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel | |
UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
CL2011002675A1 (es) | Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende. | |
PH12018500910A1 (en) | Novel method of use and compositions | |
BR112015027436A8 (pt) | composição tópica e veículo para administração de ingredientes farmaceuticamente ou cosmeticamente ativos | |
BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
BR112015002041A2 (pt) | formulação transdérmica contendo inibidores de cox | |
EA033306B1 (ru) | Стабилизированный раствор на основе активных веществ, способ получения стабилизированного раствора активных веществ, фармацевтическая композиция на основе стабилизированного раствора активных веществ (два варианта) | |
CY1109541T1 (el) | Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ | |
MX2015010967A (es) | Formulaciones transdermicas de laquinimod. | |
BR112014018426A8 (pt) | Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina | |
BR112022008849A2 (pt) | Composição para induzir imunidade a um ingrediente ativo, e, método para preparar uma composição para induzir imunidade a um ingrediente ativo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023025444-9 PROTOCOLO 870230106964 EM 04/12/2023 17:28. |